SCHEMBL2965833

SCHEMBL2965833

O=c1cc(-c2nnc(OCc3cc(-c4cccc(Cl)c4)on3)[nH]2)cc[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.47
MAPT P10636 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
NPC1 O15118 7/20 0.36
RAB9A P51151 7/20 0.36
TP53 P04637 2/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
THRB P10828 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HRH1 P35367 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CXCR1 P25024 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2958377 0.80 GRM5 (0.67) GRM5MAPTNPC1RAB9ATP53
SCHEMBL2966743 0.80 GRM5 (0.71) GRM5MAPTTDP1MEN1KMT2A
SCHEMBL2913730 0.68 GRM5 (0.57) GRM5ADORA3ADORA2BADORA1NPC1
SCHEMBL4060427 0.67 RAB9A (0.50) MAPTTDP1NPC1RAB9ATP53
SCHEMBL1544031 0.66 TP53 (0.47) MAPTTDP1MEN1KMT2AKDM4E
SCHEMBL2967216 0.64 GRM5 (1.00) GRM5NPC1RAB9ATP53THRB
SCHEMBL2966335 0.64 GRM5 (1.00) GRM5NPC1RAB9ATP53THRB
SCHEMBL1544808 0.64 NOTUM (0.69) MAPTNPC1RAB9ATP53THRB
SCHEMBL2489301 0.64 RAB9A (0.50) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL8242758 0.63 KCNH2 (0.55) GRM5MAPTTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772235-B2 mGluR5 modulators ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20080125436-A1 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting ASTRAZENECA AB (SE) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125436-A1 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting GLRA1, GRM1, GRM5 GRM5 3/4885MAPT 3245/4885TDP1 1912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.